Phase 2 Long COVID Trial, Recruiting NCT07316127 Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Condition: Long COVID
Back to Long Covid

Phase 2 Long COVID Trial, Recruiting

NCT07316127
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Long COVID based on the World Health Organization's definition of the condition
  • You experience post-exertional malaise (PEM), meaning your symptoms get significantly worse after physical or mental effort, as measured by a specific questionnaire (DSQ-PEM)
  • Your overall ability to function day-to-day is moderately affected by Long COVID, scoring between 20–70% on a scale called the Bell Disability Scale (confirm with trial site)
  • You were in good health before your Long COVID diagnosis, with no limitations on your normal daily activities

Who may not be able to join:

  • You have a significant history of serious lung or heart disease
  • You have had a heart procedure (such as a stent or similar intervention) within the last 3 months
  • You are currently taking medication that suppresses your immune system for an autoimmune condition
  • You have Type 1 diabetes
  • You have been diagnosed with a solid organ cancer (such as kidney, liver, or lung cancer) within the last 5 years
  • You have an active mental health condition that is currently being treated by a psychiatrist
  • Your Body Mass Index (BMI) is greater than 35
  • You had ongoing or long-term fatigue before your Long COVID diagnosis
  • You already had some limitations in your daily activities before your Long COVID diagnosis
  • You are currently pregnant or breastfeeding

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +31 20 566 9111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
12 December 2027

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Change in fatigue measured by the Fatigue Assessment Scale (FAS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov